Locally Advanced Non inflammatory Breast Cancer

References

• American Joint Committee on Cancer Manual for Staging of Cancer, O H Beahrs, D E Henson, R VP Hutter, et al. J.B. Lippincott, Philadelphia, PA 1992; 149–154
   Google Scholar
• Osteen R T, Winchester D P, Cunningham M P. Breast Cancer. National Cancer Data Base: Annual Review of Patient Care 1995. American Cancer Society, Atlanta, GA 1995; 12–37
   Google Scholar
• SEER Cancer Statistics Review, 1973–1994., L AG Ries, C L Kosary, B F Hankey, et al. National Cancer Institute, Bethesda, MD 1997, NIH Pub. No. 97–2789
   Google Scholar
• Helvie M A, Joynt L K, Cody R L, et al. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996; 198: 327–332
   PubMed Web of Science ®Google Scholar
• Moskovic E C, Mansi J L, King D M, et al. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol 1993; 47: 339–344
   PubMed Web of Science ®Google Scholar
• Powles T J, Hickish T F, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547–552
   PubMed Web of Science ®Google Scholar
• Herrada J, Iyer R B, Atkinson E N, et al. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 1997; 3: 1565–1569
   PubMed Web of Science ®Google Scholar
• Jansson T, Westlin J E, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 1995; 13: 1470–1477
   PubMed Web of Science ®Google Scholar
• Abraham D C, Jones R C, Jones S E, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996; 78: 91–100
   PubMed Web of Science ®Google Scholar
• Mumtaz H, Davidson T, Hall-Craggs M A, et al. Comparison of magnetic resonance imaging and conventional triple assessment in locally recurrent breast cancer. Br J Surg 1997; 84: 1147–1151
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Ames F C, Buzdar A U, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507–2516
   PubMed Web of Science ®Google Scholar
• Schwartz G F, Birchansky C A, Komarnicky L T, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73: 362–369
   PubMed Web of Science ®Google Scholar
• Swain S M, Sorace R, Bagley C, et al. Neoadjuvant chemotherapy in the combined-modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987; 47: 3889–3894
   PubMed Web of Science ®Google Scholar
• Grohn P, Heinonen E, Klefstrom, et al. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1984; 54: 670–674
   PubMed Web of Science ®Google Scholar
• Klefstrom P, Grohn P, Heinonen E, et al. Adjuvant post-operative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1987; 60: 936–942
   PubMed Web of Science ®Google Scholar
• Schaake-Koning C, Van Der Linden E H, Hart G, et al. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 1985; 11: 1759–1763
   PubMed Web of Science ®Google Scholar
• Rubens R D, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy An EORTC breast cancer co-operative group trial (10792). Eur J Cancer Clin Oncol 1989; 25: 667–678
   PubMedGoogle Scholar
• Bartelink H, Rubens R D, van der Schueren E, et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997; 15: 207–215
   PubMed Web of Science ®Google Scholar
• DeLena M, Virion M, Zucali R, et al. Multimodality treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981; 4: 229–236
   PubMedGoogle Scholar
• Perloff M, Lesnick G J, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988; 6: 261–269
   PubMed Web of Science ®Google Scholar
• Olson J E, Neuberg D, Pandya K, et al. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 1997; 79: 1138–1149
   PubMed Web of Science ®Google Scholar
• DeLena M, Zucali R, Viganotti G, et al. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978; 1: 53–59
   PubMed Web of Science ®Google Scholar
• Chittoor S, Swain S. Management of stage III breast cancer: locally advanced breast cancer. The Breast: Comprehensive Management of Benign and Malignant Diseases, K I Bland, E M Copeland. WB Saunders, Philadelphia 1998; 1260–1298
   Google Scholar
• Buzdar A U, Singletary S E, Booser D J, et al. Combined modality treatment of stage III and inflammatory breast cancer. Surg Oncol Clin North Am 1995; 4: 715–734
   PubMedGoogle Scholar
• Pierce L J, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy upon local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992; 23: 949–960
   PubMed Web of Science ®Google Scholar
• Sorace R A, Bagley C S, Lichter A S, et al. The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. World J Surg 1985; 9: 775–785
   PubMed Web of Science ®Google Scholar
• Veronesi A, Frustaci S, Tirelli U, et al. Tamoxifen therapy in post-menopausal advanced breast cancer: efficacy at the primary tumor site in 46 evaluable patients. Tumori 1981; 67: 235–238
   PubMed Web of Science ®Google Scholar
• Campbell F C, Morgan D AL, Bishop H M, et al. The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study. J Clin Oncol 1984; 10: 111–115
   Web of Science ®Google Scholar
• Gazet J C, Ford H T, Coombes R C. Randomized trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). Br J Cancer 1991; 63: 279–282
   PubMed Web of Science ®Google Scholar
• Anderson E DC, Forrest A PM, Hawkins R A, et al. Primary systemic therapy for operable breast cancer. Br J Cancer 1991; 63: 561–566
   PubMed Web of Science ®Google Scholar
• Willsher P C, Robertson J FR, Chan S Y, et al. Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 1997; 33: 45–49
   PubMed Web of Science ®Google Scholar
• Sjovall M P, Malmstrom P. Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer. Acta Oncol 1997; 36: 207–212
   PubMed Web of Science ®Google Scholar
• Scholl S M, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial: S6. Eur J Cancer 1994; 30A: 645–652
   PubMed Web of Science ®Google Scholar
• Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 1991; 2: 347–354
   PubMed Web of Science ®Google Scholar
• Semiglazov V F, Topuzov E E, Bavli J L, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 591–595
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local- regional disease in women with operable breast cancer: findings from National Surgical Adjuvant breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483–2493
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E, et al. Effect of preoperative therapy for primary breast cancer (BC) on local-regional disease, disease-free survival (DFS) and survival (S): results from NSABP B-18 [abstract 449]. Proc Am Soc Clin Oncol 1997; 16: 127a
   Google Scholar
• Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995; 45: 227–243
   PubMed Web of Science ®Google Scholar
• Chollet P H, Chanier S, Brain E, et al. Neoadjuvant chemotherapy in breast cancer. High pathological response rate induced by intensive anthracycline-based regimen. Proc Am Soc Clin Oncol 1995; 14: A218
   Google Scholar
• Cocconi G, diBlasio Bisagni G, et al. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol 1990; 13: 226
   PubMed Web of Science ®Google Scholar
• Conte P F, Alama A, Bertelli G. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer 1987; 40: 490–494
   PubMed Web of Science ®Google Scholar
• Gradishar W J. Phase II study: preliminary results: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 1997; 11(Suppl 8)15–18
   PubMedGoogle Scholar
• Hobar P C, Jones R C, Schouten J, et al. Multimodality treatment of locally advanced breast carcinoma. Arch Surg 1988; 123: 951–955
   PubMed Web of Science ®Google Scholar
• Piccart M J, De Valeriola D, Paridaens R, et al. Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 1988; 62: 2501–2506
   PubMed Web of Science ®Google Scholar
• Rasbridge S A, Gillett C E, Seymour A M, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis, and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994; 70: 335–341
   PubMed Web of Science ®Google Scholar
• Singletary S E, McNeese M D, Hortobagyi G N. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992; 69: 2849–2852
   PubMed Web of Science ®Google Scholar
• Smith I E, Walsh G, Jones A, et al. High complete rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424–429
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539–1545
   PubMed Web of Science ®Google Scholar
• Feldman L D, Hortobagyi G N, Buzdar A U, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578–2581
   PubMed Web of Science ®Google Scholar
• Piccart M J, Bruning P, Wildiers J, et al. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclo-phosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. Ann Oncol 1995; 6: 673–677
   PubMed Web of Science ®Google Scholar
• Antman K H, Rowlings P A, Vaughan W P, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879
   PubMed Web of Science ®Google Scholar
• Dittrich C, Jakesz R, Gnant M, et al. Preoperative paclitaxel (TOL) in the first-line therapy of patients with breast cancer T3/ 4, NO-3, M0, followed by surgery, CMF ± tamoxifen and radiotherapy—phase II trial. Proc Am Soc Clin Oncol 1997; 16: 166a, (abstract)
   Google Scholar